P.2.c.006 Efficacy and clinical relevance of vilazodone in the treatment of major depressive disorder: a pooled analysis of phase III clinical trials

2012 ◽  
Vol 22 ◽  
pp. S253-S254
Author(s):  
A. Khan ◽  
W. Song ◽  
J. Edwards ◽  
A. Ruth
Keyword(s):  
Clinical Trials ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Clinical Relevance ◽  
Pooled Analysis ◽  
Phase Iii ◽  
Major Depressive ◽  
Phase Iii Clinical Trials

A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder

2008 ◽  
Vol 23 (4) ◽  
pp. 188-197 ◽  
Author(s):  
Daniel Z. Lieberman ◽  
Stuart A. Montgomery ◽  
Karen A. Tourian ◽  
Claudine Brisard ◽  
Gregory Rosas ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Pooled Analysis ◽  
Controlled Trials ◽  
Major Depressive

scholarly journals Efficacy of levomilnacipran extended-release in major depressive disorder: pooled analysis of 5 double-blind, placebo-controlled trials

CNS Spectrums ◽  
2014 ◽  
Vol 20 (2) ◽  
pp. 148-156 ◽  
Author(s):  
Stuart A. Montgomery ◽  
Carl P. Gommoll ◽  
Changzheng Chen ◽  
William M. Greenberg
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Extended Release ◽  
Rating Scale ◽  
Pooled Analysis ◽  
Major Depressive ◽  
Double Blind ◽  
Madrs Score ◽  
Wide Range ◽  
Remission Rates

Introduction/ObjectivePost hoc analyses were conducted to evaluate the efficacy of levomilnacipran extended-release (ER) in subgroups of patients with major depressive disorder (MDD).MethodsData were pooled from 5 completed Phase II/III studies. Patients were categorized by sex, age, MDD duration, recurrence of MDD, current episode duration, number of prior episodes, and baseline Montgomery–Åsberg Depression Rating Scale (MADRS) score. Efficacy was evaluated by MADRS least squares (LS) mean change from baseline, response (MADRS improvement ≥50%), and remission (MADRS ≤10).ResultsIn the pooled population, treatment with levomilnacipran ER versus placebo resulted in greater improvement in MADRS score (−15.8 versus −12.9; LS mean difference, −2.9; P < .001) and higher response rates (44.7% versus 34.5%; P < .001). Comparable treatment effects were found in most subgroups. Remission rates in the overall population were higher for levomilnacipran ER versus placebo (27.7% versus 21.5%; P < .05); notably high remission rates were seen in patients with baseline MADRS score < 30 (48.8% versus 28.9%; P < .001).DiscussionClinically meaningful improvements in depressive symptoms were found across subgroups, including statistically significant outcomes for both response and remission.ConclusionLevomilnacipran ER was efficacious across a wide range of MDD patients, including men and women, ages 18–78, with varying histories and symptom severity.

Sign in / Sign up

Export Citation Format

Share Document